Affordable Access

Publisher Website

JN403,in vitrocharacterization of a novel nicotinic acetylcholine receptor α7 selective agonist

Neuroscience Letters
Publication Date
DOI: 10.1016/j.neulet.2007.01.045
  • Nicotinic α7 Acetylcholine Receptors
  • Partial Agonist
  • Calcium Influx
  • Xenopusoocytes
  • Jn403
  • Biology


Abstract This report describes the in vitro features of a novel selective nicotinic acetylcholine receptor (nAChR) α7 agonist, JN403, (S)-(1-Aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid (S)-1-(2-fluoro-phenyl)-ethyl ester. JN403 was evaluated in a number of in vitro systems of different species, at recombinant receptors using radioligand binding, signal transduction and electrophysiological studies. When using [ 125I] α-bungarotoxin (α-BTX) as a radioligand, JN403 has high affinity for human recombinant nAChR α7 (p K D = 6.7). Functionally, JN403 is a partial and potent agonist at human nAChR α7. The compound stimulates calcium influx in GH3 cells recombinantly expressing the human nAChR with an pEC 50 of 7.0 and an E max of 85% (compared to the full agonist epibatidine). In Xenopus oocytes expressing human nAChR α7 JN403 induces inward currents with an pEC 50 of 5.7 and an E max of 55%. In both recombinant systems JN403 is a partial agonist and the agonistic effects are blocked after pre-administration of methyllycaconitine (MLA, 100 nM), a nAChR α7 antagonist. In functional calcium influx assays, JN403 displays a significantly lower potency for other subtypes of human nAChRs like α4β2, α3β4, α1β1γδ as well as 5HT 3 receptors when tested functionally as an antagonist (pIC 50 < 4.8) and is devoid of agonistic activity (pEC 50 < 4). Similarly, JN403 shows low binding activity at a wide panel of neurotransmitter receptors. Thus, JN403 is a potent and selective nAChR α7 agonist and will be a useful tool for the characterization of nAChR α7 mediated effects both in vitro and in vivo.

There are no comments yet on this publication. Be the first to share your thoughts.